Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Nathalie Spielewoy"'
Autor:
Günter Fingerle-Rowson, Tina Nielsen, Jeffrey M. Venstrom, Christian Klein, Andres Cardona, Christopher R. Bolen, Nathalie Spielewoy, Deniz Sahin, Andrea Knapp, Harald Zeuner, Valentin Goede, Alexandra Bazeos, Umberto Vitolo, Laurie H. Sehn, Robert Marcus, Wolfgang Hiddemann, Marek Trněný, Mikkel Z. Oestergaard, Magdalena Klanova
Purpose:Natural killer (NK) cells are key effector cells for anti-CD20 monoclonal antibodies (mAb), such as obinutuzumab and rituximab. We assessed whether low pretreatment NK-cell count (NKCC) in peripheral blood or tumor tissue was associated with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70b5efac80c8286475bb0868688eb644
https://doi.org/10.1158/1078-0432.c.6528176
https://doi.org/10.1158/1078-0432.c.6528176
Autor:
Günter Fingerle-Rowson, Tina Nielsen, Jeffrey M. Venstrom, Christian Klein, Andres Cardona, Christopher R. Bolen, Nathalie Spielewoy, Deniz Sahin, Andrea Knapp, Harald Zeuner, Valentin Goede, Alexandra Bazeos, Umberto Vitolo, Laurie H. Sehn, Robert Marcus, Wolfgang Hiddemann, Marek Trněný, Mikkel Z. Oestergaard, Magdalena Klanova
Baseline patient and disease characteristics in FL and DLBCL patients with NKCCs available (analysis population) and in the GALLIUM and GOYA ITT populations.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ebc5ad55bc74698cc02be8b8ab219f7
https://doi.org/10.1158/1078-0432.22472264
https://doi.org/10.1158/1078-0432.22472264
Autor:
Günter Fingerle-Rowson, Tina Nielsen, Jeffrey M. Venstrom, Christian Klein, Andres Cardona, Christopher R. Bolen, Nathalie Spielewoy, Deniz Sahin, Andrea Knapp, Harald Zeuner, Valentin Goede, Alexandra Bazeos, Umberto Vitolo, Laurie H. Sehn, Robert Marcus, Wolfgang Hiddemann, Marek Trněný, Mikkel Z. Oestergaard, Magdalena Klanova
Association between baseline peripheral blood NKCC and tumor NK cell gene expression in FL (A) and DLBCL (B)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1dd681789354e95b95eedb7f0cb0f7c1
https://doi.org/10.1158/1078-0432.22472267.v1
https://doi.org/10.1158/1078-0432.22472267.v1
Autor:
Marek Trněný, Kathryn Humphrey, Nathalie A. Johnson, Sven de Vos, Gilles Salles, Farheen Mir, Richard Greil, Yanwen Jiang, Elizabeth Punnoose, Robin Gasiorowski, Arijit Sinha, Su Y. Kim, Caterina Patti, Emma Clark, Andrew D. Zelenetz, Jean-François Larouche, Nathalie Spielewoy, Divya Samineni, Alexandra Bazeos, Franck Morschhauser, Pierre Feugier, Pieternella J. Lugtenburg, Árpád Illés, Ian W. Flinn
Publikováno v:
Blood, 137(5), 600-609. American Society of Hematology
Blood
Blood
The phase 2 CAVALLI (NCT02055820) study assessed efficacy and safety of venetoclax, a selective B-cell lymphoma-2 (Bcl-2) inhibitor, with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in first-line (1L) diffuse la
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68ae5b032ae11d17b10939b5f59777af
https://doi.org/10.1182/blood.2020006578
https://doi.org/10.1182/blood.2020006578
Autor:
Ian W. Flinn, Nathalie Spielewoy, F. Morschhauser, Robin Gasiorowski, S. de Vos, Marek Trněný, Richard Greil, Gilles Salles, Martin Kornacker, Jean-François Larouche, Arijit Sinha, P. Feugier, Farheen Mir, Elizabeth Punnoose, Árpád Illés, Nathalie A. Johnson, Caterina Patti, Pieternella J. Lugtenburg, Adam M. Petrich, Andrew D. Zelenetz, Divya Samineni, Alexandra Bazeos, Kathryn Humphrey, Edith Szafer-Glusman
Publikováno v:
Hematological Oncology. 37:135-137
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3bae84a5f74b2ccc49dda567aea064b3
https://doi.org/10.1002/hon.95_2629
https://doi.org/10.1002/hon.95_2629
Autor:
Christiane Pott, Laurie H. Sehn, Nathalie Spielewoy, Bruce D. Cheson, Eva Hoster, Guenter Fingerle-Rowson, Chris Harbron, E. Nicolas-Virelizier, David Belada, Brad S. Kahl, John G. Gribben, Kirsten Mundt, Britta Kehden, Elisabeth Wassner-Fritsch
Publikováno v:
Leukemia
We report assessment of minimal residual disease (MRD) status and its association with outcome in rituximab-refractory follicular lymphoma (FL) in the randomized GADOLIN trial (NCT01059630). Patients received obinutuzumab (G) plus bendamustine (Benda
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9f31ed0173bfa5f65086f69e5542d2d
https://pubmed.ncbi.nlm.nih.gov/31462735
https://pubmed.ncbi.nlm.nih.gov/31462735
Autor:
Magdalena Klanova, Jeffrey M. Venstrom, Marek Trněný, Mikkel Z. Oestergaard, Christian Klein, Umberto Vitolo, Andrea Knapp, Valentin Goede, Tina Nielsen, Robert Marcus, A. Cardona, Deniz Sahin, Wolfgang Hiddemann, Alexandra Bazeos, Laurie H. Sehn, Christopher R. Bolen, Harald Zeuner, Günter Fingerle-Rowson, Nathalie Spielewoy
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 25(15)
Purpose: Natural killer (NK) cells are key effector cells for anti-CD20 monoclonal antibodies (mAb), such as obinutuzumab and rituximab. We assessed whether low pretreatment NK-cell count (NKCC) in peripheral blood or tumor tissue was associated with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b39f2b109bbac8541bb96e67bc69f099
https://pubmed.ncbi.nlm.nih.gov/31053601
https://pubmed.ncbi.nlm.nih.gov/31053601
Autor:
Kim Linton, Felipe A. Castro, Ellie White, Adam Gibb, John Radford, Aijing Shang, Andy Surinach, Michael Wenger, Nathalie Spielewoy, Anshuman Chaturvedi
Publikováno v:
Blood. 134:2917-2917
Introduction: First-line (1L) therapy for diffuse large B-cell lymphoma (DLBCL) can cure ~60% of patients (pts), but ~10-15% do not respond and 20-25% relapse. Salvage chemotherapy with autologous stem cell transplant (ASCT) is standard for 'fit' pts
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d57a8eea8496439e1306b8e6b56017d2
https://doi.org/10.1182/blood-2019-123664
https://doi.org/10.1182/blood-2019-123664
Autor:
Martin Kornacker, Farheen Mir, Marek Trněný, Nathalie A. Johnson, Adam M. Petrich, Andrew D. Zelenetz, Nathalie Spielewoy, Gilles Salles, Robin Gasiorowski, Richard Greil, Pieternella J. Lugtenburg, Caterina Patti, P. Feugier, F. Morschhauser, Ian W. Flinn, Elizabeth Punnoose, Árpád Illés, S. de Vos, Arijit Sinha, Jean-François Larouche, Edith Szafer-Glusman, Divya Samineni, Alexandra Bazeos
Publikováno v:
HemaSphere. 3:99
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a2021c2ef903f5793e041f092a3c3de9
https://doi.org/10.1097/01.hs9.0000559388.41193.da
https://doi.org/10.1097/01.hs9.0000559388.41193.da
Autor:
John R. Yates, Curt Wittenberg, Mabelle Ashe, Nathalie Spielewoy, Marisela Guaderrama, James A. Wohlschlegel
Publikováno v:
Eukaryotic Cell. 9:592-601
Npr2, a putative “nitrogen permease regulator” and homolog of the human tumor suppressor NPRL2 , was found to interact with Grr1, the F-box component of the SCF Grr1 (Skp1–cullin–F-box protein complex containing Grr1) E3 ubiquitin ligase, by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd2830f9c7bce114b0729ef9619801ed
https://doi.org/10.1128/ec.00192-09
https://doi.org/10.1128/ec.00192-09